519 related articles for article (PubMed ID: 23078431)
1. Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
Komatsu-Tanaka M; Iwakiri R; Fujimoto K; Fujiwara Y; Inamori M; Tanaka J; Shimatani T; Akiyama J; Ando T; Manabe N; Kinjo F; Deguchi R; Kusano M
Dig Endosc; 2012 Nov; 24(6):407-11. PubMed ID: 23078431
[TBL] [Abstract][Full Text] [Related]
2. Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.
Suzuki T; Matsushima M; Masui A; Tsuda S; Imai J; Nakamura J; Tsukune Y; Uchida T; Yuhara H; Igarashi M; Koike J; Mine T
World J Gastroenterol; 2015 Apr; 21(16):5023-31. PubMed ID: 25945018
[TBL] [Abstract][Full Text] [Related]
3. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
Hongo M; Miwa H; Kusano M;
J Gastroenterol Hepatol; 2012 May; 27(5):913-8. PubMed ID: 22142515
[TBL] [Abstract][Full Text] [Related]
4. [Long-term impact on quality of life in patients with gastroesophageal reflux disease after 52-week rabeprazole treatment].
Yang XL; Liu XH; Ke MY; Song ZQ; Yuan YZ; Luo JY; Hou XH
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(34):2404-7. PubMed ID: 20137694
[TBL] [Abstract][Full Text] [Related]
5. Response to gastroesophageal reflux disease therapy: assessment at 4 weeks predicts response/non-response at 8 weeks.
Kusano M; Hongo M; Miwa H
Digestion; 2012; 85(4):282-7. PubMed ID: 22538343
[TBL] [Abstract][Full Text] [Related]
6. Observational comparative trial of the efficacy of proton pump inhibitors versus histamine-2 receptor antagonists for uninvestigated dyspepsia.
Nagahara A; Asaoka D; Hojo M; Oguro M; Shimada Y; Ishikawa D; Osada T; Kawabe M; Yoshizawa T; Otaka M; Watanabe S
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S122-8. PubMed ID: 20586853
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
Kawara F; Fujita T; Morita Y; Uda A; Masuda A; Saito M; Ooi M; Ishida T; Kondo Y; Yoshida S; Okuno T; Yano Y; Yoshida M; Kutsumi H; Hayakumo T; Yamashita K; Hirano T; Hirai M; Azuma T
World J Gastroenterol; 2017 Mar; 23(11):2060-2067. PubMed ID: 28373773
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
Miwa H; Sasaki M; Furuta T; Koike T; Habu Y; Ito M; Fujiwara Y; Wada T; Nagahara A; Hongo M; Chiba T; Kinoshita Y;
Aliment Pharmacol Ther; 2007 Jul; 26(1):69-77. PubMed ID: 17555423
[TBL] [Abstract][Full Text] [Related]
9. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
Bytzer P; van Zanten SV; Mattsson H; Wernersson B
Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
[TBL] [Abstract][Full Text] [Related]
10. [Oesophageal acid exposure test in non-erosive gastroesophageal reflux disease and the diagnostic value of rabeprazole].
Fan YH; Lü B; Zhan LX; Zhang L
Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):475-7. PubMed ID: 17663823
[TBL] [Abstract][Full Text] [Related]
11. [The quality of life dynamics in patients with gastroesophageal reflux disease during rabeprazol therapy].
Maev IV; Samsonov AA; Odintsova AN; Golubev NN; Iablunovskaia GI
Eksp Klin Gastroenterol; 2009; (4):97-100. PubMed ID: 19967818
[TBL] [Abstract][Full Text] [Related]
12. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease.
Lee ES; Kim N; Lee SH; Park YS; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
Aliment Pharmacol Ther; 2009 Jul; 30(2):154-64. PubMed ID: 19392871
[TBL] [Abstract][Full Text] [Related]
13. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetics to proton pump inhibitor therapy.
Miyamoto M; Haruma K; Takeuchi K; Kuwabara M
J Gastroenterol Hepatol; 2008 May; 23(5):746-51. PubMed ID: 18028348
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.
Yamaji Y; Isomura Y; Yoshida S; Yamada A; Hirata Y; Koike K
J Dig Dis; 2014 Sep; 15(9):469-76. PubMed ID: 24957863
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria.
Xiao YL; Peng S; Tao J; Wang AJ; Lin JK; Hu PJ; Chen MH
Am J Gastroenterol; 2010 Dec; 105(12):2626-31. PubMed ID: 20823838
[TBL] [Abstract][Full Text] [Related]
16. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease.
Nojkov B; Rubenstein JH; Adlis SA; Shaw MJ; Saad R; Rai J; Weinman B; Chey WD
Aliment Pharmacol Ther; 2008 Mar; 27(6):473-82. PubMed ID: 18194508
[TBL] [Abstract][Full Text] [Related]
17. Effect of baseline symptom severity on patient-reported outcomes in gastroesophageal reflux disease.
Junghard O; Wiklund IK
Eur J Gastroenterol Hepatol; 2007 Jul; 19(7):555-60. PubMed ID: 17556901
[TBL] [Abstract][Full Text] [Related]
18. [The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease].
Liu XH; Ke MY; Song ZQ; Luo JY; Yuan YZ; Hou XH; Zhu YL; Sun J; Zha H
Zhonghua Nei Ke Za Zhi; 2005 Nov; 44(11):818-21. PubMed ID: 16316559
[TBL] [Abstract][Full Text] [Related]
19. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
[TBL] [Abstract][Full Text] [Related]
20. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association.
Aanen MC; Weusten BL; Numans ME; de Wit NJ; Samsom M; Smout AJ
J Clin Gastroenterol; 2008; 42(5):441-7. PubMed ID: 18344896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
